Skip to main
KRRO

KRRO Stock Forecast & Price Target

KRRO Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Korro Bio Inc has recently made significant advancements in its development of KRRO-121, a liver-targeted RNA editing drug, which has demonstrated the ability to stabilize glutamine synthetase and improve ammonia clearance, a critical factor given the unmet needs in treating urea cycle disorders and hepatic encephalopathy. The strong preclinical data from mouse and non-human primate studies suggest robust safety and efficacy, coupled with a potential market opportunity of approximately $1.5 billion to $2.0 billion for these conditions. With KRRO-121's Investigational New Drug (IND) filing anticipated in the second half of 2026, Korro Bio’s strategic progress and the promising pharmacoeconomic upside create a positive outlook for its stock.

Bears say

Korro Bio has experienced significant stock selloff following disappointing results from its KRRO-110 AATD program, highlighting the ongoing concerns regarding the efficacy of its pipeline candidates. The company's risk profile is further exacerbated by potential delays in clinical trial advancements, the necessity for favorable clinical data from ongoing programs, and the threat of long-term dilution due to funding requirements. Additionally, uncertainties surrounding regulatory interpretations and possible obsolescence of its therapies due to advancements from competitors contribute to a cautious outlook on Korro Bio's financial stability and market position.

KRRO has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Frequency Therapeutics Inc (KRRO) Forecast

Analysts have given KRRO a Buy based on their latest research and market trends.

According to 8 analysts, KRRO has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Frequency Therapeutics Inc (KRRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.